Advertising
Showing 1 to 15 of 58 entries
BUY
LLY vs. NVO NVO is focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
biotechnology / pharmaceutical
TOP PICK
Diabetes is an epidemic and LLY is a leader in therapeutics for this disease. Also it is making a major impact in the diagnostics and monitoring of Alzheimer's. Healthcare in general is one of the three best performing industries of all time but has under-performed until the beginning of this year. It has spun off its animal health division. It is defensive and timely in a bear market. Buy 16, Hold 8, Sell 1.
biotechnology / pharmaceutical
BUY
Now, you need boring, low PE stocks, the opposite of those hurt by inflation, such as Alphabet or Meta. They sell at historically cheap PEs. In healthcare, Eli Lilly is his top pick.
biotechnology / pharmaceutical
TOP PICK
There is an epidemic in Diabetes and it is in this field. Also in area of Alzheimers. Has made advancements in diagnostic tools and monitoring and treating patients. This is a defensive business not affected by a slowing economy. Buy 16 Hold 8 Sell 1
biotechnology / pharmaceutical
COMMENT
They report Thursday. They have drugs for Alzheimer's and diabetes in its pipeline.
biotechnology / pharmaceutical
STRONG BUY
As the Fed is about to raise interest rates, buy companies that make real, concrete things. This includes pharmas. Since he started buying this in October, it's rallied. It's up 58% YTD. Last week, it held an investor day and soared 10% in one day, but then pulled back. Why he likes it? Their drug pipeline is the best in the industry. They spend a lot on R&D. In 2014, LLY that began delivering20 new drugs to the market. Seven could do north of $3 billion in sales, or 58% of company revenues. They won't lost patent protection for several years. Obesity, dementia and RNA-based drugs are their three main areas of focus. The first two are large (and sadly growing) markets. Their Alzheimer's drug data has been stronger than Biogen's. 2022 will see (likely, he feels) approval of these two drugs and could amount to $10-15 billion in sales. Great managers. Operating margin has leapt from 20.7% to 30%; managers predict rising to 35%. Their 2022 outlook is bullish with rising EPS. Plans to raise dividends and buyback shares in the future. R&D spending results in high results (revenues). Oncology is another area of strength.
biotechnology / pharmaceutical
BUY
They hold an investor meeting on Wednesday. He expects good reports about several drugs: one for diabetes, another for Alzheimer's, which could be multi-billion franchises later.
biotechnology / pharmaceutical
BUY
A play on their Alzheimer's drug. He's long liked this.
biotechnology / pharmaceutical
BUY
The catalyst is the higher volumes from more people with diabetes. Diabetes is expected to rise by 20% by 2050. Lots of room to thrive. Novo Nordisk is first out of the gate and has an oral pill. LLY is not bad either.
biotechnology / pharmaceutical
BUY
Trades at 34x PE, because investors believe in LLY's new Alzheimer's drug. Also, all drug stocks are rallying because of the Delta variant and calls for a booster shot.
biotechnology / pharmaceutical
COMMENT
Eli bounced today off Biogen's monster move after the FDA greenlit the latter's Alzheimer's drug.
biotechnology / pharmaceutical
BUY
A fave of his, up 19% YTD. Last month they delivered a terrific quarter and strong phase 2 data on their Alzheimer's drug, a possible game-changer. They also have a Covid antibody treatment that's already selling well. Most recentlty they delivered good phase 3 trial results on their cholesterol, weighr-loss drug for diabetes.
biotechnology / pharmaceutical
RISKY BUY
Allan Tong’s Discover Picks LLY stock is now flirting with 52-week highs and trading above its 50- and 200-day moving averages. It trades at 25.55x and pays a 1.64% dividend. Essentially, positive news on March 12 will launch the LLY stock—and alleviate the suffering of many people and their families—but negative headlines will sink it, which might make it an even bigger bargain stock. Read 3 Bargain Stocks: Eli Lilly, Unilever & Apple for our full analysis.
biotechnology / pharmaceutical
BUY
Recent great results on phase 2 of Alzheimer's testing. There will be a lot of focus on the results around March 12. It it works, tremendous upside. Huge for families and for LLY. Diabetes franchise is performing extremely well. Oncology is building out.
biotechnology / pharmaceutical
COMMENT
Their stock has rallied so much after vaccine hopes that it's now cooling off. Their pipeline of drugs is super. Any further positive news about their Alzheimer's drug push this stock higher.
biotechnology / pharmaceutical
Showing 1 to 15 of 58 entries

Eli Lilly & Co.(LLY-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Eli Lilly & Co. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Eli Lilly & Co.(LLY-N) Frequently Asked Questions

What is Eli Lilly & Co. stock symbol?

Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N

Is Eli Lilly & Co. a buy or a sell?

In the last year, 7 stock analysts published opinions about LLY-N. 7 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..

Is Eli Lilly & Co. a good investment or a top pick?

Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..

Why is Eli Lilly & Co. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Eli Lilly & Co. worth watching?

7 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.

What is Eli Lilly & Co. stock price?

On 2022-06-29, Eli Lilly & Co. (LLY-N) stock closed at a price of $323.